Julie Jones is the Founder and CEO of BioValeo, a New Zealand-based Contract Research Organization (CRO) providing services to companies developing Precision or Personalized Medicine Interventions.

As medicine progresses, treatments are becoming more specific and tailored to the individual patient. Rather than bundling patients according to a high-level disease category, next generation treatments offer targeted intervention based on a specific set of characteristics - i.e., via their genetic or other biomarkers, for example. With this increased "Precision" or "Personalization", comes additional complexity, cost and regulatory scrutiny.

Join us in Episode 7 where Julie and I discuss how Precision or Personalized Medicine trial differ from the "status quo" and why a bespoke CRO is needed to support these trials; the long-term healthcare and economic benefits of developing the supporting infrastructure for Precision/Personalized medicine trials; the exciting developments happening in this space in New Zealand....and much much more.

You can find out more about Julie and BioValeo here:
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]

-

Subscribe for free on Spotify - [ Ссылка ]

Get in touch in the comments below or head to: [ Ссылка ]

Precision Medicine Research is Not for the Faint of Heart | Julie Jones | Good Clinical | Ep_7
#medicine #precisionmedicine #personalizedmedicine #research #clinicaltrials #clinicalresearch #podcast #podcasts #medicine #healthcare #medicalresearch #venturecapital #startup #startups #entrepreneur #entrepreneurship

свернуть